Literature DB >> 9059665

A nomenclature system for the aldo-keto reductase superfamily.

J M Jez1, T G Flynn, T M Penning.   

Abstract

As new members of the AKR superfamily are identified the need for a systematic and expandable nomenclature has risen, especially since some members of the superfamily have multiple names based on substrate specificity. We have proposed a nomenclature system for the AKR superfamily that is similar to the P450 system but based on amino acid sequence comparisons instead of nucleotide sequence comparisons. Our system uses percent amino acid identities to delineate families and subfamilies within the larger superfamily. Although there are not as many AKRs as P450s, having a flexible nomenclature system will allow for easy incorporation of new proteins into the superfamily.

Mesh:

Substances:

Year:  1997        PMID: 9059665     DOI: 10.1007/978-1-4615-5871-2_66

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

1.  AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.

Authors:  Linlin Zhong; Honglin Shen; Chenfei Huang; Hongwu Jing; Deliang Cao
Journal:  Toxicol Appl Pharmacol       Date:  2011-05-26       Impact factor: 4.219

2.  Structure-function characterization of an aldo-keto reductase involved in detoxification of the mycotoxin, deoxynivalenol.

Authors:  Nadine Abraham; Kurt L Schroeter; Yan Zhu; Jonathan Chan; Natasha Evans; Matthew S Kimber; Jason Carere; Ting Zhou; Stephen Y K Seah
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 3.  Aldo-keto reductase (AKR) superfamily: genomics and annotation.

Authors:  Rebekka D Mindnich; Trevor M Penning
Journal:  Hum Genomics       Date:  2009-07       Impact factor: 4.639

4.  The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoate induced esophageal squamous cell carcinoma cell death.

Authors:  Wei Li; Guixue Hou; Dianrong Zhou; Xiaomin Lou; Yang Xu; Siqi Liu; Xiaohang Zhao
Journal:  Oncotarget       Date:  2016-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.